These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15611810)

  • 1. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults.
    Weiss K; Low DE; Cortes L; Beaupre A; Gauthier R; Gregoire P; Legare M; Nepveu F; Thibert D; Tremblay C; Tremblay J
    Can Respir J; 2004; 11(8):589-93. PubMed ID: 15611810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteremic pneumococcal pneumonia associated with macrolide failure.
    Dylewski J; Davidson R
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):39-42. PubMed ID: 16411124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia.
    Dwyer R; Ortqvist A; Aufwerber E; Henriques Normark B; Marrie TJ; Mufson MA; Torres A; Woodhead MA; Alenius M; Kalin M
    Eur J Clin Microbiol Infect Dis; 2006 Aug; 25(8):518-21. PubMed ID: 16896822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.
    Waterer GW; Somes GW; Wunderink RG
    Arch Intern Med; 2001 Aug 13-27; 161(15):1837-42. PubMed ID: 11493124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K; Tillotson GS
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality.
    Lujan M; Gallego M; Fontanals D; Mariscal D; Rello J
    Crit Care Med; 2004 Mar; 32(3):625-31. PubMed ID: 15090938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia.
    Jover F; Cuadrado JM; Andreu L; Martínez S; Cañizares R; de la Tabla VO; Martin C; Roig P; Merino J
    Eur J Intern Med; 2008 Jan; 19(1):15-21. PubMed ID: 18206596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia.
    Cilloniz C; Albert RK; Liapikou A; Gabarrus A; Rangel E; Bello S; Marco F; Mensa J; Torres A
    Am J Respir Crit Care Med; 2015 Jun; 191(11):1265-72. PubMed ID: 25807239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.
    Martínez JA; Horcajada JP; Almela M; Marco F; Soriano A; García E; Marco MA; Torres A; Mensa J
    Clin Infect Dis; 2003 Feb; 36(4):389-95. PubMed ID: 12567294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
    Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
    Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
    Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
    Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
    Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial.
    Figueiredo-Mello C; Naucler P; Negra MD; Levin AS
    Clin Microbiol Infect; 2018 Feb; 24(2):146-151. PubMed ID: 28648859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia.
    Chokshi R; Restrepo MI; Weeratunge N; Frei CR; Anzueto A; Mortensen EM
    Eur J Clin Microbiol Infect Dis; 2007 Jul; 26(7):447-51. PubMed ID: 17534677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone.
    García Vázquez E; Mensa J; Martínez JA; Marcos MA; Puig J; Ortega M; Torres A
    Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):190-5. PubMed ID: 15782278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.